Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Aug;8(4):550-552.
doi: 10.21037/tlcr.2019.03.06.

Osimertinib in first line setting: for Asian patients

Keisuke Onoi  1 , Yoshiko Kaneko  1 , Junji Uchino  1
Affiliations
Editorial

Osimertinib in first line setting: for Asian patients

Keisuke Onoi et al. Transl Lung Cancer Res. 2019 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: J Uchino received grants from AstraZeneca K.K. The funder had no role in the writing of the manuscript. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92. 10.1056/NEJMoa044238 - DOI - PubMed
    1. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73. 10.1371/journal.pmed.0020073 - DOI - PMC - PubMed
    1. Hanna N, Johnson D, Temin S, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017;35:3484-515. 10.1200/JCO.2017.74.6065 - DOI - PubMed
    1. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR -Mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378:113-25. 10.1056/NEJMoa1713137 - DOI - PubMed
    1. Nakao A, Hiranuma O, Uchino J, et al. Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial. Oncologist 2019. [Epub ahead of print]. 10.1634/theoncologist.2019-0003 - DOI - PMC - PubMed